1 – 50 of 151
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
(
- Contribution to journal › Article
- 2023
-
Mark
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
(
- Contribution to journal › Article
-
Mark
Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma– pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia
(
- Contribution to journal › Article
-
Mark
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
(
- Contribution to journal › Article
- 2022
-
Mark
Fibrinogen-like protein 2 in gastrointestinal stromal tumour
(
- Contribution to journal › Article
-
Mark
SELNET clinical practice guidelines for bone sarcoma
(
- Contribution to journal › Article
-
Mark
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments
(
- Contribution to journal › Article
-
Mark
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
(
- Contribution to journal › Scientific review
-
Mark
Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes : Pooled Analysis of Population-Based Studies
(
- Contribution to journal › Article
- 2021
-
Mark
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)
(
- Contribution to journal › Article
-
Mark
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities
(
- Contribution to journal › Article
-
Mark
Adjuvant imatinib for GIST : duration likely matters
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy : Results from the EUROpean Bone Over 40 Sarcoma Study
(
- Contribution to journal › Article
-
Mark
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors : An Analysis of a Randomized Clinical Trial after 10-Year Follow-up
(
- Contribution to journal › Article
-
Mark
Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic
(
- Contribution to journal › Article
-
Mark
Rare cancers of unknown etiology : lessons learned from a European multi-center case–control study
(
- Contribution to journal › Article
- 2019
-
Mark
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
(
- Contribution to journal › Article
-
Mark
Mitotic Count and Estimation of the Risk of GIST Recurrence in Patients Treated with Preoperative Imatinib
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Tobacco smoking and alcohol consumption as risk factors for thymoma – A European case-control study
(
- Contribution to journal › Article
- 2018
-
Mark
Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors—A Scandinavian Sarcoma Group study (SSG XX)
(
- Contribution to journal › Article
-
Mark
Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
Working to improve the management of sarcoma patients across Europe : A policy checklist
(
- Contribution to journal › Article
-
Mark
EURO-B.O.S.S. : A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma
(
- Contribution to journal › Article
-
Mark
Occupational exposure to organic solvents and risk of male breast cancer : A European multicenter case-control study
(
- Contribution to journal › Article
-
Mark
Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
(
- Contribution to journal › Article
-
Mark
Gastrointestinal stromal tumours : ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
- 2017
-
Mark
The Scandinavian Sarcoma Group Central Register : 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma
(
- Contribution to journal › Article
-
Mark
Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib : An exploratory analysis of a randomized clinical trial
(
- Contribution to journal › Article
-
Mark
SLUG transcription factor : A pro-survival and prognostic factor in gastrointestinal stromal tumour
(
- Contribution to journal › Article
- 2016
-
Mark
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.
(
- Contribution to journal › Article
-
Mark
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
(
- Contribution to journal › Article
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
(
- Contribution to journal › Article
-
Mark
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
(
- Contribution to journal › Article
-
Mark
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma : a Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1) : an open-label, international, randomised controlled trial
(
- Contribution to journal › Article
- 2015
-
Mark
F-18-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
(
- Contribution to journal › Article
-
Mark
Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.
(
- Contribution to journal › Article
-
Mark
Post-Relapse Survival in Patients With Ewing Sarcoma
(
- Contribution to journal › Article
-
Mark
Referral patterns, treatment and outcome of high-grade malignant bone sarcoma in Scandinavia-SSG Central Register 25 years' experience.
(
- Contribution to journal › Article
-
Mark
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
(
- Contribution to journal › Article
-
Mark
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
(
- Contribution to journal › Article
-
Mark
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase 2 study by The Nordic Lymphoma Group.
(
- Contribution to journal › Article
- 2014
-
Mark
Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.
(
- Contribution to journal › Article
-
Mark
Risk Factors for Gastrointestinal Stromal Tumor Recurrence in Patients Treated With Adjuvant Imatinib
(
- Contribution to journal › Article
-
Mark
High-Dose Chemotherapy with Stem Cell Rescue in the Primary Treatment of Metastatic and Pelvic Osteosarcoma: Final Results of the ISG/SSG II Study
(
- Contribution to journal › Article
-
Mark
Gastrointestinal Stromal Tumor: A Method for Optimizing the Timing of CT Scans in the Follow-up of Cancer Patients.
(
- Contribution to journal › Article
-
Mark
Trusted computing for infrastructure
(
- Contribution to specialist publication or newspaper › Specialist publication article
- 2013
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis.
(
- Contribution to journal › Article